Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia 6Blast Crisis 6Leukemia, Myeloid, Accelerated Phase 5Leukemia, Myeloid, Acute 4Myeloproliferative Disorders 3Neoplasms by Histologic Type 2Neoplasms 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Bone Marrow Diseases 2Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Philadelphia Chromosome 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Cyclophosphamide 8fludarabine 4Rituximab 4Melphalan 3tetulomab tetraxetan lu-177 2ponatinib 2fludarabine phosphate 2entrectinib 2atezolizumab 2alectinib 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lutetium 2Etoposide 2Doxorubicin 2Busulfan 2Brentuximab Vedotin 2Bortezomib 2Bone Marrow Transplantation 2trametinib 1pertuzumab 1penpulimab 1pembrolizumab 1ibritumomab tiuxetan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × ponatinib × Lymphoid × Clear all
NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Takeda

Phase 1/2 Completed
35 enrolled 36 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡